Market Research Report
Osteosarcoma - Market Insights, Epidemiology and Market Forecast - 2030
|Published by||DelveInsight Business Research LLP||Product code||963734|
|Published||Content info||264 Pages
Delivery time: 1-2 business days
|Osteosarcoma - Market Insights, Epidemiology and Market Forecast - 2030|
|Published: October 14, 2020||Content info: 264 Pages||
DelveInsight's 'Osteosarcoma-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Osteosarcoma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Osteosarcoma market size from 2017 to 2030. The Report also covers current Osteosarcoma treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Osteosarcoma (osteogenic sarcoma) is the most common type of bone cancer that usually develops in the osteoblast cells of the bone. It mostly occurs in the long bones around the knee. Other sites include the upper leg, or thighbone, the lower leg, upper arm bone, or any bone in the body, including those in the pelvis, shoulder, and skull. It may spread to nearby tissues, such as tendons or muscles, and may also metastasize through the bloodstream to other organs or bones in the body.
It can be classified as primary or secondary based on the location and spread of cancer. When cancer starts in bone tissue, it is called primary bone cancer. Whereas, when cancer cells travel to the bone from elsewhere, it is called secondary or metastatic bone cancer. Furthermore, based on the histological features, it can be categorized into high-grade, intermediate-grade, and low-grade Osteosarcoma; each category has different subtypes.
Pain is the most common symptom of Osteosarcoma; this pain may come and go at first, but, gradually, it becomes constant. Some patients may have swelling or a mass in the area of the tumor. If the tumor is located in the leg, the patient may also develop a limp. Osteosarcoma weakens the bones, and patients may develop pathologic bone fractures in the area of the tumor.
The signs or symptoms first suspect the diagnosis of Osteosarcoma. The diagnosis usually started by examining the medical history and physical examination. Imaging techniques, blood tests, and biopsy are used to confirm the diagnosis of Osteosarcoma and classification into stages.
Continued in the report…..
Osteosarcoma is treated with a combination of therapies that can include surgery, chemotherapy, and radiation therapy. Most patients with high-grade tumors receive about 3 months of chemotherapy, known as neoadjuvant therapy, before surgery.
Most osteosarcomas are high-grade and require multimodal treatment, mainly chemotherapy, and surgery. Low-grade osteosarcoma (including parosteal and low-grade central) does not require chemotherapy, but if the histological examination of a resected tumor shows high-grade areas, chemotherapy is recommended.
The most common combinations of chemotherapy include high-dose methotrexate, doxorubicin, and cisplatin (sometimes with ifosfamide); doxorubicin and cisplatin; ifosfamide and etoposide; and ifosfamide, cisplatin (or carboplatin), and epirubicin.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Osteosarcoma, Gender-specific Incident Cases of Osteosarcoma, Age-specific Incident Cases of Osteosarcoma, Stage-specific Incident Cases of Osteosarcoma, Sub-types specific Incident Cases of Osteosarcoma, and Site-specific Incident Cases of Osteosarcoma scenario of Osteosarcoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
The epidemiology segment also provides the Osteosarcoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The drug chapter segment of the Osteosarcoma report encloses the detailed analysis of Osteosarcoma marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Osteosarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.
Osteosarcoma Marketed Drugs
Mepact (Mifamurtide): Takeda
Mepact is an intravenous formulation containing mifamurtide as an active ingredient. It is approved in children, adolescents, and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection and is used in combination with postoperative multiagent chemotherapy. Mepact is available as a vial containing powder for reconstitution and one single-use filter. The active substance in Mepact, mifamurtide, is an immunomodulator. It works by activating macrophages and monocytes. The precise way that mifamurtide works in osteosarcoma is not fully understood, but it is thought to cause the white blood cells to release chemicals that kill the cancerous cells. Mepact is not approved in the US; however, some osteosarcoma patients have been able to obtain Mepact in the United States through the FDA's compassionate use and personal importation programs. The FDA also designated patient affairs staff that may help navigate the access process.
Products detail in the report…
Khapzory (levoleucovorin): Acrotech Biopharma
Khapzory (levoleucovorin) injection, folate analog, is approved for rescue after high-dose methotrexate therapy in patients with osteosarcoma. Rescue recommendations are based on a methotrexate dose of 12 grams/m2 administered by intravenous infusion over 4 h. The rescue is initiated at a dose of 7.5 mg (approximately 5 mg/m2) every 6 h, 24 h after the beginning of the methotrexate infusion and is continued until the methotrexate level is below 0.05 µM. Khapzory is available as an intravenous administration only. It is also approved for diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination and for treatment of patients with metastatic colorectal cancer in combination with fluorouracil.
Products detail in the report…
Osteosarcoma Emerging Drugs
Lenvatinib: Eisai Limited
Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2, and VEGFR3 kinases. Currently, the company is investigating this molecule in Phase II stage of development for Osteosarcoma.
Products detail in the report…
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). This drug shows anti-angiogenic activity due to its dual-targeted VEGFR2-TIE2 tyrosine kinase inhibition. Currently. The company is evaluating this molecule in Phase II stage of development for the treatment of patients with Osteosarcoma.
Products detail in the report…
Cabozantinib S-malate: Exelixis
Cabozantinib sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second-line treatment for renal cell carcinoma among others. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Currently, the company is investigating this molecule in Phase II stage of development for the treatment of patients with advanced Ewing sarcoma or osteosarcoma.
Products detail in the report…
List to be continued in the report…
The United States contributes to the major share of the Osteosarcoma market as compared to other countries, such as EU5 (Italy, Spain, United Kingdom, France, and Germany) and Japan.
In general, the commonly available modalities for the treatment of osteosarcoma include chemotherapy, surgery and radiation therapy. Although some novel insights have been offered for clinical and scientific relevance, minor progress has been made in Osteosarcoma treatment following a significant survival improvement in the late 1980s with the addition of chemotherapy to surgery. The most widely used chemotherapeutic drugs include cisplatin, doxorubicin, ifosfamide, and high-dose methotrexate with leucovorin calcium rescue (HDMTX), or a combination of these. The use of these agents results in an approximately 60-70% increase in the overall survival. However, successful treatment is obtained in about ~70% of patients with localized disease and ~20-30% with the metastatic disease which shows that disease in the later stages has a poor prognosis.
The mainstream chemotherapeutic agents for treatment include methotrexate, doxorubicin, cisplatin, and ifosfamide approved by the NCCN Guidelines. Since the introduction of chemotherapy, single-agent treatment of osteosarcoma is considered inadequate, the majority of osteosarcoma treatment is based on a combination of two or more of only four drugs: doxorubicin, cisplatin, methotrexate, and ifosfamide. Therefore, treatment options available for first-line osteosarcoma patients consist of combinations including doxorubicin + cisplatin (DC), methotrexate + doxorubicin + cisplatin (MDC), and methotrexate + doxorubicin + cisplatin + ifosfamide (MDCI).
The function of second-line chemotherapy for recurrent Osteosarcoma is much less well defined and there is no accepted standard regimen. The National Comprehensive Cancer Network (NCCN) guidelines recommend that second-line (relapsed/refractory or metastatic) preferred therapies include ifosfamide (high dose) and etoposide, regorafenib, sorafenib, sorafenib Radium 223 chloride, and everolimus. Other preferred regimens include cyclophosphamide and topotecan, docetaxel and gemcitabine, gemcitabine alone. The other regimens which are useful under certain circumstances as per NCCN guidelines include cyclophosphamide and etoposide, ifosfamide with carboplatin and etoposide, high dose methotrexate, high dose methotrexate with etoposide and ifosfamide, Sm-EDTMP for relapsed refractory disease beyond the second line.
Apart from these treatment regimens, there are few FDA approved products for osteosarcoma including Fusilev and Khapzory, both folate analogs used for the rescue after high-dose methotrexate therapy in patients with osteosarcoma. Fusilev was approved by FDA in 2008 and recently its patent got expired after that it was discontinued from the market. The company then introduced a drug Khapzory with the same generic (Levoleucovorin). The drug was later approved by the FDA in 2018 for the same indication. Furthermore, In March 2009, the European Commission granted a marketing authorization valid throughout the European Union for Mepact to IDM Pharm. This product is not approved in the United States. Nevertheless, some osteosarcoma patients have been able to obtain Mepact in the United States through the FDA's compassionate use and personal importation programs.
According to DelveInsight, Osteosarcoma 7MM is expected to change in the study period 2017-2030.
This section provides the total Osteosarcoma market size and; market size by therapies in the United States.
The total Osteosarcoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Osteosarcoma market size and market size by therapies in Japan are provided.
This section focusses on the rate of uptake of the potential drugs recently launched in the Osteosarcoma market or expected to get launched in the market during the study period 2017-2030. The analysis covers Osteosarcoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Osteosarcoma Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Osteosarcoma emerging therapies.
Reimbursement Scenario in Osteosarcoma
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Osteosarcoma market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: